Helix Biopharma Corp. HBPCF
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.71% | -38.60% | 93.60% | -80.29% | 82.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.94% | -45.91% | -42.71% | -81.85% | -18.67% |
| Operating Income | 53.94% | 45.91% | 42.71% | 81.85% | 18.67% |
| Income Before Tax | 54.95% | 48.27% | 25.76% | 82.06% | 19.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.95% | 48.27% | 25.76% | 82.06% | 19.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.95% | 48.27% | 25.76% | 82.06% | 19.45% |
| EBIT | 53.94% | 45.91% | 42.71% | 81.85% | 18.67% |
| EBITDA | 53.85% | 45.90% | 42.70% | 81.86% | 18.65% |
| EPS Basic | 68.78% | 65.80% | 52.00% | 86.74% | 35.13% |
| Normalized Basic EPS | 68.75% | 66.39% | 52.00% | 86.80% | 35.35% |
| EPS Diluted | 68.78% | 65.80% | 52.00% | 86.74% | 35.13% |
| Normalized Diluted EPS | 68.75% | 66.39% | 52.00% | 86.80% | 35.35% |
| Average Basic Shares Outstanding | 44.01% | 52.56% | 54.77% | 35.98% | 24.41% |
| Average Diluted Shares Outstanding | 44.01% | 52.56% | 54.77% | 35.98% | 24.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |